Targeting sphingosine kinase 1 to sensitise acute myeloid leukaemia to BH3 mimetic therapy [ 2018 - 2020 ]

Research Grant

Researchers: Prof Stuart Pitson (Principal investigator) ,  Dr Jason Powell

Brief description Acute Myeloid Leukaemia (AML) patients are currently treated with chemotherapeutics and despite their success at achieving disease remission these responses are often short lived, resulting in relapse and death. We have identified sphingosine kinase 1 as a new drug target in AML. This proposal aims to examine the role of targeting sphingosine kinase 1 in combination with new targeted therapies in patient samples and preclinical mouse models of AML.

Funding Amount $AUD 679,385.07

Funding Scheme Project Grants

Notes Standard Project Grant